Health Experts Say Weight Loss Pills 'Not the Answer'
Last Thursday, the U.S. Food and Drug Administration (FDA) approved market release of Contrave, a new anti-obesity drug manufactured by Orexigen, a U.S. company in partnership with Japan’s Takeda Pharmaceuticals. Yet the Wall Street Journal’s Chelsey Dulaney reported that, “Despite the approval, shares of Orexigen fell as much as 13% Thursday. Analysts noted that Contrave's label didn't include the interim results of a cardiovascular trial, which showed that the drug didn't dramatically increase patients' risk of a heart attack.” The...
View full press release